VistaGen Therapeutics, Inc. CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--At the Society for Biomolecular Sciences (SBS) Stem Cell Symposium today in Anaheim, California, H. Ralph Snodgrass, Ph.D., President and CEO of VistaGen Therapeutics, Inc., will present an overview of the Company’s latest embryonic stem (ES) cell-based drug discovery and development advances. VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.